After months of litigation, Yale New Haven called a deal to buy Prospect’s three Connecticut hospitals “impossible.” The bankrupt health system is reportedly looking for new buyers.
Prospect, Yale New Haven hospital deal appears dead in the water Read More »
Novo Nordisk’s NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less than half of its list price.
Novo Launches DTC Program for Wegovy, Cutting Price to $499 a Month Read More »
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ Read More »
At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 K27M-mutated diffuse glioma.
Jazz Expands Cancer Expertise With $935M Chimerix Buy Read More »
En los últimos años, el sector de las apuestas deportivas online ha experimentado un crecimiento exponencial, consolidándose como una de las industrias de entretenimiento más rentables del mundo. Este auge no solo se debe a los avances tecnológic …
Tendencias actuales en apuestas deportivas online Read More »
The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to lower drug prices.
Novo, Sanofi Hit With Anti-Competitive Probe in South Africa: Bloomberg Read More »
Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger Read More »
The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC advisory committee meetings.
FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount Read More »
A BioSpace analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer them found that 2024 was the busiest year yet. Companies have disclosed spending $513 million on vouchers that were earned in 2024 so far.
La evolución se asocia tradicionalmente a un proceso de incremento de la complejidad y ganancia de nuevos genes. Sin embargo, se ha comprobado que perder genes es un proceso mucho más frecuente en la evolución de las especies de lo que se pensaba y que puede favorecer nuevas ada …
Mejorar mediante la pérdida de genes, un camino evolutivo más habitual de lo creído Read More »
